Table 8.

All treatment-emergent adverse events involving diarrhea, alopecia, or neutropenia

MedDRA SOC	MedDRA preferred term	Vidofludimus (N = 122)	Placebo (N = 119)	Total (N = 241)
Gastrointestinal disorders	Diarrhea	7 (5.7)	7 (5.9)	14 (5.8)
Skin and subcutaneous tissue disorders	Alopecia	1 (0.8)	0 (0.0)	1 (0.4)
Blood and lymphatic system disorders	White blood cell disorder	0 (0.0)	1 (0.8)	1 (0.4)
Investigations	Neutrophil count abnormal	0 (0.0)	1 (0.8)	1 (0.4)

Data are expressed as n (%)

MedDRA Medical Dictionary for Regulatory Activities, N number of patients, SOC system organ class